Cystectomy for Bladder Cancer: A Contemporary Series

Dalbagni, Guido; Genega, Elizabeth M.; Hashibe, Mia; ZHANG, ZUO-FENG; Russo, Paul; Herr, Harry W.; Reuter, Vincent

doi:10.1097/00005392-200104000-00012

Cited by 82 publications

(129 citation statements)

References 19 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…52 Data that have accumulated in the 47 years since this original publication do not appear to support the subdivision of T2 by depth of muscularis propria invasion (Table 2). 5, During a mean follow-up of 8.3 years, Cheng et al 85 found no survival difference between pT2a and pT2b cancer ( Figure 14). Ten-year cancer specific survival rates were 82 and 81%, respectively, for patients with pT2a and pT2b bladder cancer.…”

Section: Stage Pt2 Carcinomamentioning

confidence: 94%

“…The incidence of stage pT0 bladder carcinoma is approximately 10%. 5,[10][11][12][13][14] Unlike stage pT0 cancer of the prostate (so called 'vanishing cancer phenomenon'), the clinical outcome among patients with stage pT0 bladder cancer is variable. In the largest series of pT0 carcinomas (120 patients), the 5-year recurrence-free, cancer-specific, and overall survivals were 84, 88, and 84%, respectively.…”

Section: Stage Pt0 Carcinomamentioning

confidence: 99%

“…1 Pathological stage is the most important determinant of prognosis and treatment for bladder cancer. [2][3][4][5][6] An ideal staging system should accurately reflect the natural history of cancer at this site, describe the total cancer burden, assess the extent of spread at the time of diagnosis, and stratify patients into prognostic groups for treatment planning. Adoption of a uniform staging system permits comparison of therapeutic interventions among different institutions.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Staging and reporting of urothelial carcinoma of the urinary bladder

et al. 2009

View full text Add to dashboard Cite

Section: Stage Pt2 Carcinomamentioning

confidence: 94%

Section: Stage Pt0 Carcinomamentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Staging and reporting of urothelial carcinoma of the urinary bladder

et al. 2009

View full text Add to dashboard Cite

“…5a, Table 2). Urothelial carcinoma has long been known to have a remarkable propensity for divergent differentiation, which is seen most commonly in association with high-grade and locally advanced disease [59][60][61][62]. The incidence of divergent differentiation in cystectomy specimens is as high as 33%.…”

Section: Invasive Urothelial Carcinoma With Divergent Differentiationmentioning

confidence: 99%

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours

et al. 2016

View full text Add to dashboard Cite

It has been 12 yr since the publication of the last World Health Organization (WHO) classification of tumours of the prostate and bladder. During this time, significant new knowledge has been generated about the pathology and genetics of these tumours. Intraductal carcinoma of the prostate is a newly recognized entity in the 2016 WHO classification. In most cases, it represents intraductal spread of aggressive prostatic carcinoma and should be separated from high-grade prostatic intraepithelial neoplasia. New acinar adenocarcinoma variants are microcystic adenocarcinoma and pleomorphic giant cell adenocarcinoma. Modifications to the Gleason grading system are incorporated into the 2016 WHO section on grading of prostate cancer, and it is recommended that the percentage of pattern 4 should be reported for Gleason score 7. The new WHO classification further recommends the recently developed prostate cancer grade grouping with five grade groups. For bladder cancer, the 2016 WHO classification continues to recommend the 1997 International Society of Urological Pathology grading classification. Newly described or better defined noninvasive urothelial lesions include urothelial dysplasia and urothelial proliferation of uncertain malignant potential, which is frequently identified in patients with a prior history of urothelial carcinoma. Invasive urothelial carcinoma with divergent differentiation refers to tumours with some percentage of "usual type" urothelial carcinoma combined with other morphologies. Pathologists should mention the percentage of divergent histologies in the pathology report. PATIENT SUMMARY Intraductal carcinoma of the prostate is a newly recognized entity in the 2016 World Health Organization classification. Better defined noninvasive urothelial lesions include urothelial dysplasia and urothelial proliferation of uncertain malignant potential. v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j AbstractIt has been 12 yr since the publication of the last World Health Organization (WHO) classification of tumours of the prostate and bladder. During this time, significant new knowledge has been generated about the pathology and genetics of these tumours.

show abstract

“…3 Currently, radical cystectomy (RC) is the standard of care for the management of organ-confined muscle invasive or high-risk superficial disease. [4][5][6][7][8] About 10% of patients (range: 5-20) will have no evidence of tumour at pathological examination of the cystectomy specimen; such patients are designated stage pT0. 6,[8][9][10] The clinical outcomes and significance of patients with stage pT0 disease at cystectomy is unclear.…”

Section: Introductionmentioning

confidence: 99%

Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder

Sandhu

Aprikian

Chin

et al. 2013

CUAJ

View full text Add to dashboard Cite

Introduction: Radical cystectomy is the standard treatment for muscle invasive bladder cancer. We assessed clinical outcomes in patients found to have no evidence of disease (i.e., pT0N0) following radical cystectomy. Methods: We collected and pooled a database of 2287 patients who underwent radical cystectomy between 1993 and 2008 in eight centres across Canada. Of this number, 135 patients were found to have pT0N0 bladder cancer at the time of cystectomy. Survival data and prognostic variables were analyzed using KaplanMeier method and Cox proportional hazard regression analysis. Results: Median patient age was 66 years with a mean follow-up of 42 months. Clinical stage distribution was Tis 8.9%, Ta 1.5%, T1 20.7%, T2 45.2%, T3 5.2%, and T4 5.2%. The five-year recurrence-free survival (RFS), disease-specific survival (DSS) and overall survival (OS) were 83%, 96%, and 88%, respectively. The 10-year RFS, DSS and OS were 66%, 92%, and 70%, respectively. On Cox proportional regression analysis, no variables were associated with disease recurrence and only patient age was associated with overall survival. Interpretation: Patients with pT0N0 pathology after cystectomy have excellent outcomes with high five-and 10-year RFS, DSS and OS. However, there is still a risk of tumour recurrence in this patient population and thus postoperative surveillance is still required.

show abstract

Cystectomy for Bladder Cancer: A Contemporary Series

Cited by 82 publications

References 19 publications

Staging and reporting of urothelial carcinoma of the urinary bladder

Staging and reporting of urothelial carcinoma of the urinary bladder

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours

Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder

Contact Info

Product

Resources

About